

> ACUTE BACTERIAL MENINGITIS


# INFECTIONS OF THE NERVOUS SYSTEM

ACUTE BACTERIAL MENINGITIS

臨床表現 (_NEJM_ 2006;354:44; _Lancet_ 2012;380:1684)

• **Fever** (77%), **headache** (87%), **stiff neck** (31%), **photosensitivity**, Δ **MS** (69%) (defined as GCS <14), **seizures** (5%); 2 of 4 (fever, HA, stiff neck, Δ MS) present in 95%

• Presentation may be _atypical_ (eg, lethargy without fever) in elderly and immunosupp.

Physical exam

• **Nuchal rigidity** (Se 31%), **Kernig’s sign** (Pt supine, hip flexed at 90°, knee flexed at 90°; ⊕ if passive extension of knee → resistance), **Brudzinski’s sign** (Pt supine and limbs supine; ⊕ if passive neck flexion → involuntary hip and/or knee flexion)

nb, Kernig’s or Brudzinski’s signs ⊕ in only ~10% of 病人 (_Lancet_ 2012;380:1684)

• ± Focal neuro findings (~30%; hemiparesis, aphasia, visual field cuts, CN palsies)

• ± Funduscopic findings: papilledema, absent venous pulsations

• ± HEENT findings: sinus tenderness, clear rhinorrhea (CSF leak)

• ± Skin findings: petechial rash (_N. meningitidis_), genital or oral ulcers (HSV)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Microbiology in Bacterial Meningitis</b> <span>(<i>NEJM</i> 2011;364:2016)</span></p></td></tr><tr><td><p><b>Etiology</b></p></td><td><p><b>Comments</b></p></td></tr><tr><td><p><b><i>S. pneumoniae</i></b> (30–60%)</p></td><td><p>Assess for distant infxn (eg, Osler’s triad = meningitis, PNA, IE)</p><p>Drug-resistant <i>S. pneumoniae:</i></p><p>~40% PCN-resistant (even <i>intermediate</i> resistance problematic)</p><p>~&lt;10% 3<sup>rd</sup>-gen. cephalosporin-resistant</p><p>Vaccine may have reduced rate of invasive disease</p></td></tr><tr><td><p><b><i>N. meningitidis</i></b> (10–35%)</p></td><td><p>Primarily in those &lt;30 y; may be a/w petechiae or purpura. Deficiencies in terminal complement predispose to recurrent meningococcemia &amp; rarely meningitis.</p><p>Vaccine rec for all adolescents, college freshmen living in dorm, military recruits, s/p splenectomy or C5-9 deficiency</p></td></tr><tr><td><p><b><i>H. influenzae</i></b> (&lt;5%)</p></td><td><p>↓ Incidence in children b/c vaccine. Look for risk factors in adults (eg, CSF leak, neurosurgical procedure, trauma, mastoiditis).</p></td></tr><tr><td><p><i>L. monocytogenes</i> (5–10%)</p></td><td><p>↑ Incid in elderly, alcoholics or 病人 with cancer, immunosupp. or iron overload. Outbreaks a/w contaminated dairy &amp; raw vegetables. Despite name, a/w <i>poly-predominant</i> pleocytosis.</p></td></tr><tr><td><p>GNRs (1–10%)</p></td><td><p>Usually health care associated, postprocedure or in elderly or immunosuppressed</p></td></tr><tr><td><p><i>Staphylococci</i> (5%)</p></td><td><p>Seen with indwelling CSF shunt (<i>S. epidermidis</i>) or following neurosurgery or head trauma (<i>S. aureus</i>)</p></td></tr><tr><td><p>Mixed infection</p></td><td><p>Suspect parameningeal focus or CSF leak</p></td></tr><tr><td><p>Fungal</p></td><td><p>Seen if immunosuppressed or after neurosurgery</p></td></tr></tbody></table>

Sequential approach to bacterial meningitis

(1) Stat **BCx** → **antibiotics** + **corticosteroids** (see below)

(2) Consider CT head (if indicated, see below)

(3) **LP** (if not contraindicated); yield of CSF cx unlikely to be changed if obtained within ~4 h of initiation of 抗生素

Diagnostic studies (_NEJM_ 2017;388:3036)

• **Blood cultures** ×**2 _before 抗生素_**

• **WBC count:** >10,000 in >90% of bacterial meningitis in healthy hosts

• **Head CT** to 排除 mass effect before LP _if_ ≥1 high-risk feature: immunosupp., h/o CNS disease, new-onset seizure, focal neuro findings, papilledema (_CID_ 2004;39:1267)

• **Lumbar puncture** (_NEJM_ 2006;355:e12)

### CSF Gram stain has 30–90% Se; cx 80–90% Se if LP done prior to 抗生素

opening pressure typically ↑ in bact meningitis; must measure with Pt’s legs extended

_rule of 2s:_ CSF WBC >2k, glc <20, & TP >200 has >98% Sp for bacterial meningitis

repeat LP only if no 臨床response after 48 h of appropriate 抗生素 or CSF shunt

• Additional CSF studies based on 臨床suspicion: AFB smear & cx, India ink prep, cryptococcal Ag, fungal cx, VDRL, PCR (HSV, VZV, enteroviral), cytology

• Metagenomic next-generation sequencing ↑ dx yield (_NEJM_ 2019;380:2327)

![](https://i.imgur.com/NdrEpra.jpg)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>治療 of Bacterial Meningitis</b> <span>(<i>Lancet</i> 2012;380:1693)</span></p></td></tr><tr><td><p><b>臨床Scenario</b></p></td><td><p><b>Empiric 治療 Guidelines</b><a id="st9"></a><a href="text/part0011_split_005.html#sst9">*</a></p></td></tr><tr><td><p><b>Normal adult</b></p></td><td><p><b>Ceftriaxone 2 g IV q12h <sub>+</sub> vancomycin 15–20 mg/kg IV q12h</b></p><p>If &gt;50 y or alcoholic: add ampicillin 2 g IV q4h for <i>Listeria</i></p><p>β-lactam allergy: substitute cipro 400 mg q8h or aztreonam 2 g q6h for CTX. Substitute TMP/SMX for amp.</p></td></tr><tr><td><p><b>Immunosuppressed</b></p></td><td><p>Ampicillin + ceftazidime 2 g IV q8h + vancomycin</p></td></tr><tr><td><p><b>CSF shunts</b>, <b>recent neurosurgery, or head trauma</b></p></td><td><p>Vancomycin + ceftazidime 2 g IV q8h <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>0;362:</span><span>1</span><span>46)</span></p></td></tr><tr><td colspan="2"><p><b>Corticosteroids:</b> dexamethasone 10 mg IV q6h × 4 d → ↓ neuro disability &amp; mortality by ~50% with <i>S. pneumo</i> &amp; GCS 8–11. Consider steroids in all bacterial meningitis prior to organism identification. <b>Must start before or with 1st dose of 抗生素</b> <span>(</span><span><i>NEJM</i></span> <span>2002;347:</span><span>1</span><span>549).</span></p><p>Nb, do <i>not</i> give steroids in cryptococcal meningitis <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>6;374:542).</span></p></td></tr><tr><td colspan="2"><p><b>Prophylaxis:</b> rifampin (600 mg PO bid × 2 d) or ciprofloxacin (500 mg PO × 1) or ceftriaxone (250 mg IM × 1) for close contacts of Pt with <i>N. meningitidis</i> meningitis</p></td></tr><tr><td colspan="2"><p><b>Precautions:</b> droplet precautions until <i>N. meningitidis</i> is 排除</p></td></tr></tbody></table>

[\*](text/part0011_split_005.html#st9)When possible, organism-directed Rx, guided by sensitivities or local patterns of drug resistance should be used. In mouse model, Cftx + Ab directed against plgR and PECAM (blood–brain barrier receptors that allow _S. Pneumoniae_ to enter) → ↓ bacteria in the brain & less inflammation (_J Infect Dis_ 2018; 218:476).

Prognosis

• For community-acquired _S. pneumo_ mort. 19–37%; 30% have long-term neuro sequelae

ASEPTIC MENINGITIS

定義

• CSF pleocytosis with ⊖ blood & CSF cx; typically lymphocyte predominant

• Less likely to be bacterial, but can be infectious or noninfectious

原因 (_Neurology_ 2006;66:75)

• **Viral:** enteroviruses \[most common; if CSF ⊖ & PCR not available, test nonsterile sites (eg, nasopharyngeal, rectum)\] to help 排除\], HIV, HSV (type 2 > 1), VZV, mumps, lymphocytic choriomeningitis virus, encephalitis viruses, adenovirus, polio, CMV, EBV, WNV

• **Parameningeal focus of infection** (eg, brain abscess, epidural abscess, septic thrombophlebitis of dural venous sinuses or subdural empyema)

• **Partially treated bacterial meningitis**

• **TB**, **fungal**, **spirochetal** (Lyme, syphilis, leptospirosis), **rickettsial**, _Coxiella_, _Ehrlichia_

• **Medications:** TMP/SMX, NSAIDs, IVIG, PCN, INH, lamotrigine

• **Systemic illness:** SLE, sarcoidosis, Behçet’s, Sjögren’s syndrome, RA

• **Neoplasm:** intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis (CSF cytology or flow may be reactive and dx may require meningeal bx)

Empiric 治療

• No 抗生素 if suspect viral (cell count <500 with >50% lymphs, TP <80–100 mg/dL, normal glc, ⊖ Gram stain, not elderly/immunosupp.); otherwise start empiric 抗生素, wait for cx data

• If suspect MTb: antimycobacterial Rx + dexamethasone (_NEJM_ 2004;351:1741)

• If suspect fungal: ampho lipid formulation, ± 5-fluorouracil

ENCEPHALITIS (_NEJM_ 2018;379:557)

定義

• Infection of brain parenchyma with evidence of neurologic dysfunction

原因 (specific etiology found in <20% of cases; _Neurology_ 2006;66:75; _CID_ 2008;47:303)

• **HSV-1** all ages/seasons. If sxs recur after Rx, consider viral relapse vs. autoimmune encephalitis b/c high rates of autoimmune disease wks later (_Lancet Neurol_ 2018;17:760).

• **VZV** 1° or reactivation; ± vesicular rash; all ages (favors elderly), all seasons

• **Arboviruses:** West Nile, Eastern/Western equine, St. Louis, Japanese, Powassan (_NEJM_ 2005;353:287): fever, HA, **flaccid paralysis**, rash. Risk factors for severe renal dis., cancer, EtOH, DM, HTN (_Am J Trop Med Hyg_ 2012;87:179).

• **Enteroviruses** (coxsackie, echo): viral syndrome; peaks in late summer/early fall

• Others: CMV, EBV, HIV, JC virus (PML), measles, mumps, rubella, rabies, flu, adenovirus

• **Non-infectious**: autoimmune/paraneoplastic (anti-NMDAR, anti-Hu, anti-Ma2, anti-CRMP5, anti-mGluR5), endocarditis, brain abscess, toxoplasmosis, TB, toxins, vasculitis, Whipple’s disease, subdural hematoma, post-infxn demyelination (eg, ADEM), seizure

臨床表現

• **Fever**, **HA,** Δ **MS**, ± seizures and **focal neuro findings** (latter atypical for viral _meningitis_)

Diagnostic studies (_CID_ 2013;57:1114)

• **Lumbar puncture:** lymphocytic pleocytosis; PCR for HSV (95% Se & Sp at 2–3 d), VZV, CMV, EBV, HIV, JC, adeno/enterovirus, W. Nile (<60% Se); W. Nile CSF IgM 80% Se

• Consider testing for autoimmune 原因 (anti-NMDAR, etc.) in approp. setting

• **MRI** (CT if unavail.); HSV withtemporal lobe involvement, W. Nile with thalamic hyperintensity

• EEG to 排除 seizure; findings in encephalitis are nonspecific (temporal lobe focus in HSV)

治療

• HSV, VZV: acyclovir 10 mg/kg IV q8h (often empiric Rx given frequency of HSV/VZV)

• CMV: ganciclovir ± foscarnet; supportive care for most other 原因

BELL’S PALSY

定義 & etiology

• Acute idiopathic unilat. **facial nerve palsy** (CN VII), often presumed HSV-1 reactivation

臨床表現

• Unilateral **facial muscle weakness**, **hyperacusis**, ↓ taste/lacrimation/salivation

Diagnosis

• Dx of exclusion: 排除 brainstem lesion, Lyme (often bilateral), zoster (incl _sine herpete_), HIV/AIDS, sarcoid (often bilateral)

治療 (_NEJM_ 2007;357:1598; _JAMA_ 2009;302:985)

• ~80% recover spontaneously by 9 mo (much lower rate in DM)

• Corticosteroids (prednisolone 25 mg PO bid × 10 d) started within 72 h of sx onset improve odds of recovery (note: no conclusive data for use in DM, immunosupp.)

• No conclusive data to support the use of acyclovir or valacyclovir

ZOSTER

定義 & etiology

• Zoster = herpes zoster = shingles: acute, unilat., **painful dermatomal skin eruption**

• VZV reactivation in peripheral nerve distribution from latency in dorsal root ganglion

臨床表現

• **Neuritic pain in a dermatomal distribution**, then acute **dermatomal eruption of clustered rash** (vesicles > papules/pustules > macules) in varying stages of evolution

• Consecutive dermatomes may be seen in all 病人; more widespread in immunosupp.

• Lesions in V1 distribution of facial nerve require urgent ophthalmologic evaluation

• Post-herpetic neuralgia (PHN) = severe pain lasting >90 d after episode; may last mos to y, more frequent with ↑ age and delay of antiviral Rx

Diagnosis

• Appearance of rash; DFA is most Se from scrape of newly unroofed vesicle. Tzanck does not distinguish HSV or VZV, cx insensitive for VZV (unlike HSV).

治療

• Rx if can initiate **w/in 72 h of skin lesions** in healthy Pt or at **_any time_ in immunosupp**

• Valacyclovir or famciclovir × 7–14 d, or until lesions fully crusted; acyclovir 10 mg/kg IV q8h if dissem. or high-risk Pt (medically ill, immunosupp., V1 zoster with ophthalmic signs and symptoms, etc.)

• Prevention: Shingrix approved for 病人 >50 y. 2 doses separated by 2–6 mos (97% effective at preventing shingles, also ↓ post-herpetic neuralgia).
